Brief: Adagene Announces Clinical Trial Collaboration With Merck
22/07/2021 12:45
July 22 (Reuters) - Adagene:
* ADAGENE ANNOUNCES CLINICAL TRIAL COLLABORATION WITH MERCK
TO
ADVANCE TWO ANTI-CTLA-4 MONOCLONAL ANTIBODY PROGRAMS IN
COMBINATION THERAPY WITH KEYTRUDA
* ADAGENE - GLOBAL CLINICAL STUDIES TO EVALUATE NEOBODY
PRODUCT,
SAFEBODY PRODUCT CANDIDATE WITH KEYTRUDA FOR PATIENTS WITH
ADVANCED/METASTATIC SOLID TUMORS
Further company coverage: 978y.F MRK.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adagene
See all newsBrief: Adagene To Begin Phase 1 Study Of ADG138 For Advanced Solid Tumors In Q4 2026
Brief: Adagene Announces That Third Arc Bio Has Selected First Lead Candidate Under Amended Strategic Collaboration For Development Of Masked Cd3 T Cell Engagers Utilizing Safebody® Technology
Brief: Adagene Inc Announces Offering Of American Depositary Shares
Brief: Adagene Announces FDA Fast Track Designation For Muzastotug (Adg126)
Brief: Adagene Expands SAFEBody Deal With Exelixis To Develop Third Novel Masked Antibody-Drug Conjugate